Female genital tract infections and immunity in animal models

Mucosal Immunology, Two-Volume Set

Volumn , Issue , 2005, Pages 1613-1630

  Parr, Earl L ^a   Parr, Margaret B ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882834497     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012491543-5/50098-X     Document Type: Chapter

References (210)

1. Ada G. HIV and pandemic influenza virus: Two great infectious disease challenges. Virology 2000, 268:227-230.
2. Ada G.L., McElrath M.J. HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy. AIDS Res. Hum. Retroviruses 1997, 13:205-210.
3. Adams M., Borysiewicz L., Fiander A., Man S., Jasani B., Navabi H., Lipetz C., Evans A.S., Mason M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001, 19:2549-2556.
4. Allen T.M., Jing P., Calore B., Horton H., O'Connor D.H., Hanke T., Piekarczyk M., Ruddersdorf R., Mothé B.R., Emerson C., Wilson N., Lifson J.D., Belyakov I.M., Berzofsky J.A., Wang C., Allison D.B., Montefiori D.C., Desrosiers R.C., Wolinsky S.M., Kunstman K.J., Altman J.D., Sette A., McMichael A.J., Watkins D.I. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J. Virol. 2002, 76:10507-10511.
5. Allen T.M., Mothé B.R., Sidney J., Jing P., Dzuris J.L., Liebl M.E., Vogel T.U., O'Connor D.H., Wang X., Wussow M.C., Thomson J.A., Altman J.D., Watkins D.I., Sette A. CD8+ lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex Class I molecule Mamu-A{star operator}01: implications for vaccine design and testing. J. Virol. 2001, 75:738-749.
6. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothé B.R., Vogel T.U., Dunphy E., Liebl M.E., Emerson C., Wilson N., Kunstman K.J., Wang X., Allison D.B., Hughes A.L., Desrosiers R.C., Altman J.D., Wolinsky S., Sette A., Watkins D.I. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-390.
7. Allen T.M., Vogel T.U., Fuller D.H., Mothé B.R., Steffen S., Boyson J.E., Shipley T., Fuller J., Hanke T., Sette A., Altman J.D., Moss B., McMichael A.J., Watkins D.I. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 2000, 164:4968-4978.
8. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.-L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
9. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McClure H.M., Moss B., Robinson H.L. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 2002, 76:7625-7631.
10. 89.6 infection in Macaca nemestrina. J. Virol. 2001, 75:8589-8596.
11. André S., Seed B., Eberle J., Schraut W., Bültmann A., Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 1998, 83:1497-1503.
12. Barouch D.H., Craiu A., Santra S., Egan M.A., Schmitz J.E., Kuroda M.J., Fu T.-M., Nam J.-H., Wyatt L.S., Lifton M.A., Krivulka G.R., Nickerson C.E., Lord C.I., Moss B., Lewis M.G., Hirsch V.M., Shiver J.W., Letvin N.L. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immuno-deficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 2001, 75:2462-2467.
13. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335-339.
14. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.-H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 2001, 75:5151-5158.
15. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.-M., Wagner W., Bilska M., Craiu A., Zheng X.X., Krivulka G.R., Beaudry K., Lifton M.A., Nickerson C.E., Trigona W.L., Punt K., Freed D.C., Guan L., Dubey S., Casimiro D., Simon A., Davies M.-E., Chastain M., Strom T.B., Gelman R.S., Montefiori D.C., Lewis M.G., Emini E.A., Shiver J.W., Letvin N.L. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
16. Beatty P.R., Stephens R.S. CD8+ T lymphocyte-mediated lysis of chlamydia-infected L cells using an endogenous antigen pathway. J. Immunol. 1994, 153:4588-4595.
17. mac251: Dependence on route of challenge exposure. J. Virol. 1998, 72:4170-4182.
18. Blanchard T.J., Alcamí A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J. Gen. Virol. 1998, 79:1159-1167.
19. Bontkes H.J., de Gruijl T.D., Walboomers J.M.M., Schiller J.T., Dillner J., Helmerhorst T.J.M., Verheijen R.H.M., Scheper R.J., Meijer C.J.L.M. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 1999, 80:409-417.
20. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B.A. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immuno-deficiency virus type 1 infection. J. Virol. 1994, 68:6103-6110.
21. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E., Hahn B.H., Oldstone M.B.A., Shaw G.M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997, 3:205-211.
22. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J.L.M., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55:244-265.
23. Burkhard M.J., Valenski L., Leavell S., Dean G.A., Tompkins W.A.F. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats. Vaccine 2002, 21:258-268.
24. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., Goletti D., Borsetti A., Pace M., Fanales-Belasio E., Ridolfi B., Negri D.R.M., Sernicola L., Belli R., Corrias F., Macchia I., Leone P., Michelini Z., ten Haaft P., Buttò S., Verani P., Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001, 19:2862-2877.
25. Campo M.S. Vaccination against papillomavirus in cattle. Curr. Top. Microbiol. Immunol. 1994, 186:255-266.
26. Cao H., Mani I., Vincent R., Mugerwa R., Mugyenyi P., Kanki P., Ellner J., Walker B.D. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials in Uganda. J. Infect. Dis. 2000, 182:1350-1356.
27. Chen C.-H., Wang T.L., Hung C.-F., Pardoll D.M., Wu T.-C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000, 18:2015-2022.
28. Chen C.-H., Wang T.-L., Ji H., Hung C.-F., Pardoll D.M., Cheng W.-F., Ling M., Wu T.-C. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther. 2001, 8:128-138.
29. Chen Z.W., Craiu A., Shen L., Kuroda M.J., Iroku U.C., Watkins D.L., Voss G., Letvin N.L. Simian immunodeficiency virus evades a dominant eptope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J. Immunol. 2000, 164:6474-6479.
30. Cheng W.-F., Hung C.-F., Chai C.-Y., Hsu K.-F., He L., Ling M., Wu T.-C. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 2001, 75:2368-2376.
31. Cheng W.-F., Hung C.-F., Chai C.-Y., Hsu K.-F., He L., Rice C.M., Ling M., Wu T.-C. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J. Immunol. 2001, 166:6218-6226.
32. Cheng W.-F., Hung C.-F., Hsu K.-F., Chai C.-Y., He L., Ling M., Slater L.A., Roden R.B.S., Wu T.-C. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum. Gene Ther. 2001, 12:235-252.
33. Cotter T.W., Ramsey K.H., Miranpuri G.S., Poulsen C.E., Byrne G.I. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect. Immun. 1997, 65:2145-2152.
34. Crotty S., Miller C.J., Lohman B.L., Neagu M.R., Compton L., Lu D., Lü F.X.-S., Fritts L., Lifson J.D., Andino R. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 2001, 75:7435-7452.
35. Da Silva D.M., Eiben G.L., Fausch S.C., Wakabayashi M.T., Rudolf M.P., Velders M.P., Kast W.M. Cervical cancer vaccines: Emerging concepts and developments. J. Cell. Physiol. 2001, 186:169-182.
36. Da Silva D.M., Pastrana D.V., Schiller J.T., Kast W.M. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 2001, 290:350-360.
37. Daemen T., Regts J., Holtrop M., Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 2002, 9:85-94.
38. Darville T., Andrews C.W., Sikes J.D., Fraley P.L., Braswell L., Rank R.G. Mouse strain-dependent chemokine regulation of the genital tract T helper cell type 1 immune response. Infect. Immun. 2001, 69:7419-7424.
39. Davis N.L., Caley I.J., Brown K.W., Betts M.R., Irlbeck D.M., McGrath K.M., Connell M.J., Montefiori D.C., Frelinger J.A., Swanstorm R., Johnson P.R., Johnston R.E. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 2000, 74:371-378.
40. de Gruijl T.D., Bontkes H.J., Walboomers J.M.M., Coursaget P., Stukart M.J., Dupuy C., Kueter E., Verheijen R.H.M., Helmerhorst T.J.M., Duggan-Keen M.F., Stern P.L., Meijer C.J.L.M., Scheper R.J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J. Gen. Virol. 1999, 80:399-408.
41. de Jong A., van der Burg S.H., Kwappenberg K.M.C., van der Hulst J.M., Franken K.L.M.C., Geluk A., van Meijgaarden K.E., Drijfhout J.W., Kenter G., Vermeij P., Melief C.J.M., Offringa R. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 2002, 62:472-479.
42. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79:347-352.
43. Dubensky T.W., Liu M.A., Ulmer J.B. Delivery systems for gene-based vaccines. Mol. Med. 2000, 6:723-732.
44. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., Malley J.D., Vogel T.U., Allen T.M., Watkins D.I., Miller N., Moss B. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002, 294:270-281.
45. Evans D.T., O'Connor D.H., Jing P., Dzuris J.L., Sidney J., da Silva J., Allen T.M., Horton H., Venham J.E., Rudersdorf R.A., Vogel T., Pauza C.D., Bontrop R.E., DeMars R., Sette A., Hughes A.L., Watkins D.I. Virus-specific CTL responses select from amino acid variation in SIV Env and Nef. Nature Med. 1999, 5:1270-1276.
46. Feltkamp M.C.W., Vreugdenhil G.R., Vierboom M.P.M., Ras E., van der Burg S.H., ter Schegget J., Melief C.J.M., Kast W.M. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 1995, 25:2638-2642.
47. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 1997, 158:2278-2284.
48. Fling S.P., Sutherland R.A., Steele L.N., Hess B., D'Orazio S.E.F., Maisonneuve J.-F., Lampe M.F., Probst P., Starnbach M.N. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis. PNAS 2001, 98:1160-1165.
49. Gao X.-M., Tite J.P., Lipscombe M., Rowland-Jones S., Ferguson D.J.P., McMichael A.J. Recombinant Salmonella typhimurium strains that invade nonphagocytic cells are resistant to recognition by antigen-specific cytotoxic T lymphocytes. Infect. Immun. 1992, 60:3780-3789.
50. Garland S. Human papillomavirus update with a particular focus on cervical disease. Pathology 2002, 34:213-224.
51. Geretti A.M., Osterhaus A.D.M.E. Virus replication and evolution drive the kinetics and specificity of SIV-specific cytotoxic T lymphocytes. Immunol. Rev. 2001, 183:109-114.
52. Goldstone S.E., Palefsky J.M., Winnett M.T., Neefe J.R. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 2001, 45:502-507.
53. Gómez C.E., Rodríguez D., Rodríguez J.R., Abaitua F., Duarte C., Esteban M. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector. Vaccine 2002, 20:961-971.
54. Gorelick R.J., Benveniste R.E., Lifson J.D., Yovandich J.L., Morton W.R., Kuller L., Flynn B.M., Fisher B.A., Rossio J.L., Piatak M., Bess J.W., Henderson L.E., Arthur L.O. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost. J. Virol. 2000, 74:11935-11949.
55. Goulder P.J.R., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., Rosenberg E.S., Nguyen T., Allen R., Trocha A., Altfeld M., He S., Buncel M., Funkhouser R., Pelton S.I., Burchett S.K., McIntosh K., Korber B.T.M., Walker B.D. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334-338.
56. Goulder P.J.R., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgan B., Edwards A., McMichael A.J., Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 1997, 3:212-217.
57. Gruters R.A., van Baalen C.A., Osterhaus A.D.M.E. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 2002, 20:2011-2015.
58. Gutierrez C.M., Tinoco A., Contreras M.L., Navarro T., Calzado P., Vargas L., Reyes L., Posternak R., Rosales R. Clinical protocol. A phase II study: Efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum. Gene Ther. 2002, 13:1127-1140.
59. Han R., Cladel N.M., Reed C.A., Peng X., Budgeon L.R., Pickel M., Christensen N.D. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J. Virol. 2000, 74:9712-9716.
60. Han R., Reed C.A., Cladel N.M., Christensen N.D. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: Protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 2000, 18:2937-2944.
61. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., Hill A.V.S., Smith G.L., McMichael A. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998, 16:439-445.
62. Hanke T., McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 1999, 66:177-181.
63. Hanke T., McMichael A.J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 2000, 6:951-955.
64. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., Sharpe S.A., Cook N., Smith G.L., Watkins D.I., Cranage M.P., McMichael A.J. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 1999, 73:7524-7532.
65. Harding C.V., Pfeifer J.D. Antigen expressed by Salmonella typhimurium is processed for class I major histocompatibility complex presentation by macrophages but not infected epithelial cells. Immunology 1994, 83:670-674.
66. SF162P3. J. Virol. 2001, 75:1990-1995.
67. He Z., Wlazlo A.P., Kowalczyk D.W., Cheng J., Ziang Z.Q., Giles-Davis W., Ertl H.C.J. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000, 270:146-161.
68. Hel Z., Johnson J.M., Tryniszewska E., Tsai W.-P., Harrod R., Fullen J., Tartaglia J., Franchini G. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 2002, 20:3171-3186.
69. Hel Z., Tsai W.-P., Thornton A., Nacsa J., Giuliani L., Tryniszewska E., Poudyal M., Venzon D., Wang X., Altman J., Watkins D.I., Lu W., von Gegerfelt A., Felber B.K., Tartaglia J., Pavlakis G.N., Franchini G. Potentiation of simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 2001, 167:7180-7191.
70. Hocknell P.K., Wiley R.D., Wang X., Evans T.G., Bowers W.J., Hanke T., Federoff H.J., Dewhurst S. Expression of human immunodeficiency virus type I gp 120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J. Virol. 2002, 76:5565-5580.
71. mac239. J. Virol. 2002, 76:7187-7202.
72. Hsu K.-F., Hung C.-F., Cheng W.-F., He L., Slater L.A., Ling M., Wu T.-C. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 2001, 8:376-383.
73. Huang Y., Kong W.-P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 2001, 75:4947-4951.
74. Hung C.-F., He L., Juang J., Lin T.-J., Ling M., Wu T.-C. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J. Virol. 2002, 76:2676-2682.
75. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 1998, 188:2357-2368.
76. Igietseme J.U., Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect. Immun. 2000, 68:6798-6806.
77. Igietseme J.U., Uriri I.M., Kumar S.N., Ananaba G.A., Ojior O.O., Momodu I.A., Candal D.H., Black C.M. Route of infection that induces a high intensity of gamma interferonsecreting T cells in the genital tact produces optimal protection against Chlamydia trachomatis infection in mice. Infect. Immun. 1998, 66:4030-4035.
78. Ito J.I., Lyons J.M. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect. Immun. 1999, 67:5518-5521.
79. Iwasaki A., Stiernholm B.J.N., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 1997, 158:4591-4601.
80. Jensen E.R., Selvakumar R., Shen H., Ahmed R., Wettstein F.O., Miller J.F. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol. 1997, 71:8467-8474.
81. Ji H., Wang T.-L., Chen C.-H., Pai S.I., Hung C.-F., Lin K.-Y., Kurman R.J., Pardoll D.M., Wu T.-C. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 1999, 10:2727-2740.
82. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., Irwin C.E., Safrit J.T., Mittler J., Weinberger L., Kostrikis L.G., Zhang L., Perelson A.S., Ho D.D. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189:991-998.
83. Joag S.V., Liu Z.Q., Stephens E.B., Smith M.S., Kumar A., Li Z., Wang C., Sheffer D., Jia F., Foresman L., Adany I., Lifson J., McClure H.M., Narayan O. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 1998, 72:9069-9078.
84. Johansson M., Lycke N. Immunological memory in B-cell-deficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cells. Immunology 2001, 102:199-208.
85. Johansson M., Schön K., Ward M., Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect. Immun. 1997, 65:1032-1044.
86. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., Yang J., Montefiori D.C., Montelaro R., Wyand M.S., Desrosiers R.C. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation. J. Virol. 1999, 73:4952-4961.
87. Kadish A.S., Timmins P., Wang Y., Ho G.Y.F., Burk R.D., Ketz J., He W., Romney S.L., Johnson A., Angeletti R., Abadi M., the Albert Einstein Cervix Dysplasia Clinical Consortium Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cellmediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol. Biomarkers Prevention 2002, 11:483-488.
88. Kaul R., Plummer F.A., Kimani J., Dong T., Kiama P., Rostron T., Njagi E., MacDonald K.S., Bwayo J.J., McMichael A.J., Rowland-Jones S.L. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 2000, 164:1602-1611.
89. Kaul R., Rowland-Jones S.L., Kimani J., Fowke K., Dong T., Kiama P., Rutherford J., Njagi E., Mwangi F., Rostron T., Onyango J., Oyugi J., MacDonald K.S., Bwayo J.J., Plummer F.A. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol. Lett. 2001, 79:3-13.
90. Kaur A., Alexander L., Staprans S.I., Denekamp L., Hale C.L., McClure H.M., Feinberg M.B., Desrosiers R.C., Johnson R.P. Emergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection. Eur. J. Immunol. 2001, 31:3207-3217.
91. Kelly K.A. Cellular immunity and Chlamydia genital infection: Induction, recruitment, and effector mechanisms. Int. Rev. Immunol. 2003, 22:3-41.
92. Kent S.J., Ada G.L., Hayes E., Lewis I.M. Determining the immune mechanisms of protection from AIDS: Correlates of immunity and the development of syngeneic macaques. Immunol. Rev. 2001, 183:94-108.
93. Kent S.J., Woodward A., Zhao A. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques. J. Infect. Dis. 1997, 176:1188-1197.
94. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 1998, 72:10180-10188.
95. Kim J.J., Yang J.-S., Manson K.H., Weiner D.B. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFNγ, or IL-4 gene adjuvants. Vaccine 2001, 19:2496-2505.
96. Kim J.J., Yang J.-S., Nottingham L.K., Lee D.J., Lee M., Manson K.H., Wyand M.S., Boyer J.D., Ugen K.E., Weiner D.B. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization. Virology 2001, 285:204-217.
97. Koenig S., Conley A.J., Brewah Y.A., Jones G.M., Leath S., Boots L.J., Davey V., Pantaleo G., Demarest J.F., Carter C., et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection of mutant HIV variants and subsequent disease progression. Nature Med. 1995, 1:330-336.
98. Koup R.A., Ho D.D. Shutting down HIV. Nature 1994, 370:416.
99. Lamikanra A., Pan Z.-K., Isaacs S.N., Wu T.-C., Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T-cell responses that home to the tumor site. J. Virol. 2001, 75:9654-9664.
100. Leachman S.A., Brandsma J.L. DNA vaccines for papillomavirus infections. Vaccines for Human Papillomavirus Infection and Anogenital Disease 1999, 105-148. R. G. Landes Co., Boca Ranton. R.W. Tindle (Ed.).
101. Leachman S.A., Shylankevich M., Slade M.D., Levine D., Sundaram R.K., Xiao W., Bryan M., Zelterman D., Tiegelaar R.E., Brandsma J.L. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J. Virol. 2002, 76:7616-7624.
102. Leachman S.A., Tigelaar R.E., Shlyankevich M., Slade M.D., Irwin M., Chang E., Wu T.C., Xiao W., Pazhani S., Zelterman D., Brandsma J.L. Granulocyte-macrophage colonystimulating factor priming plus papillomavirus E6 DNA vaccination: Effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J. Virol. 2000, 74:8700-8708.
103. Lehtinen M., Dillner J. Preventive human papillomavirus vaccination. Sex. Transm. Inf. 2002, 78:4-6.
104. Leifert J.A., Lindencrona J.A., Charo J., Whitton J.L. Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine. Hum. Gene Ther. 2001, 12:1881-1892.
105. Letvin N.L., Barouch D.H., Montefiori D.C. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 2002, 20:73-99.
106. Levitsky H.I., Lazenby A., Hayashi R.J., Pardoll D.M. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J. Exp. Med. 1994, 179:1215-1224.
107. Lieberman J., Frankel F.R. Engineered Listeria monocytogenes as an AIDS vaccine. Vaccine 2002, 20:2007-2010.
108. Lifson J.D., Rossio J.L., Piatak M., Parks T., Li L., Kiser R., Coalter V., Fisher B., Flynn B.M., Czajak S., Hirsch V.M., Reimann K.A., Schmitz J.E., Ghrayeb J., Bischofberger N., Nowak M.A., Desrosiers R.C., Wodarz D. Role of CD8+ lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretrovial treatment. J. Virol. 2001, 75:10187-10199.
109. Lin K.-Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., Wu T.-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996, 56:21-26.
110. Liu D.-W., Tsao Y.-P., Hsieh C.-H., Hsieh J.-T., Kung J.T., Chiang C.-L., Huang S.-J., Chen S.-L. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol. 2000, 74:9083-9089.
111. Liu D.-W., Tsao Y.-P., Kung J.T., Ding Y.-A., Sytwu H.-K., Xiao X., Chen S.-L. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 2000, 74:2888-2894.
112. Liu W.J., Zhao K.-N., Gao F.G., Leggatt G.R., Fernando G.J.P., Frazer I.H. Polynucleotide viral vaccines: Codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2002, 20:862-869.
113. Loomis W.P., Starnbach M.N. T cell responses to Chlamydia trachomatis. Curr. Opin. Microbiol. 2002, 5:87-91.
114. MacPherson G.G., Liu L.M. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr. Top. Microbiol. Immunol. 1999, 236:33-53.
115. Matano T., Kano M., Nakamura H., Takeda A., Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J. Virol. 2001, 75:11891-11896.
116. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 1998, 72:164-169.
117. Mayer K.H., Cohen D.E., Walker B.D. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin. Infect. Dis. 2001, 32:1756-1768.
118. McMichael A., Klenerman P. HLA leaves its footprints on HIV. Science 2002, 296:1410-1411.
119. Metzner K.J., Jin Z., Lee F.V., Gettie A., Bauer D.E., Di Mascio M., Perelson A.S., Marx P.A., Ho D.D., Kostrikis L.G., Connor R.I. Effects of in vivo CD8+ T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 2000, 191:1921-1931.
120. Michel N., Osen W., Gissmann L., Schumacher T.N.M., Zentgraf H., Müller M. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002, 294:47-59.
121. Milligan G.N., Bernstein D.I., Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 1998, 160:6093-7100.
122. Moore J.P., Parren P.W.H.I., Burton D.R. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol. 2001, 75:5721-5729.
123. Morrison R.P., Caldwell H.D. Immunity to murine chlamydial genital infection. Infect. Immun. 2002, 70:2741-2751.
124. Morrison S.G., Morrison R.P. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect. Immun. 2001, 69:2643-2649.
125. Morrison S.G., Su H., Caldwell H.D., Morrison R.P. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells. Infect. Immun. 2000, 68:6979-6987.
126. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., Kast W.M., Fascio G., Marty V., Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 2000, 6:3406-3416.
127. Musey L., Hu Y., Eckert L., Christensen M., Karchmer T., McElrath M.J. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J. Exp. Med. 1997, 185:293-297.
128. Muthumani K., Bagarazzi M., Conway D., Hwang D.S., Ayyavoo V., Zhang D., Manson K., Kim J., Boyer J., Weiner D.B. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J. Med. Primatol. 2002, 31:179-185.
129. Muthumani K., Kudchodkar S., Zhang D., Bagarazzi M.L., Kim J.J., Boyer J.D., Ayyavoo V., Pavlakis G.M., Weiner D.B. Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine 2002, 20:1999-2003.
130. Nakagawa M., Stites D.P., Patel S., Farhat S., Scott M., Hills N.K., Palefsky J.M., Moscicki A.-B. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis. 2000, 182:595-598.
131. Ngo-Giang-Huong N., Candotti D., Goubar A., Autran B., Maynart M., Sicard D., Clauvel J.-P., Agut H., Costagliola D., Rouzioux C. HIV type 1-specific IgG2 antibodies: Markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retroviruses 2001, 17:1435-1446.
132. Nicholls P.K., Moore P.F., Anderson D.M., Moore R.A., Parry N.R., Gough G.W., Stanley M.A. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001, 283:31-39.
133. Nicholls P.K., Stanley M.A. Canine papillomavirus-a centenary review. J. Comp. Path. 1999, 120:219-233.
134. O'Connor D., Friedrich T., Hughes A., Allen T.M., Watkins D. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection. Immunol. Rev. 2001, 183:115-126.
135. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., Schaefer M., Doe B., Otten G.R., Ulmer J.B. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 2001, 75:9037-9043.
136. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
137. Ojcius D.M., Bravo de Alba Y., Kanellopoulos J.M., Hawkins R.A., Kelly K.A., Rank R.G., Dautry-Varsat A. Internalization of chlamydia by dendritic cells and stimulation of chlamydia-specific T cells. J. Immunol. 1998, 160:1297-1303.
138. Osen W., Peiler T., Öhlschläger P., Caldeira S., Faath S., Michel N., Müller M., Tommasino M., Jochmus I., Gissmann L. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001, 19:4276-4286.
139. Ostrow R.S., McGlennen R.C., Shaver M.K., Kloster B.E., Houser D., Faras A.J. A rhesus monkey model for sexual transmission of a papillomavirus isolated from a squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 1990, 87:8170-8174.
140. Ourmanov I., Brown C.R., Moss B., Carroll M., Wyatt L., Pletneva L., Goldstein S., Venzon D., Hirsch V.M. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 2000, 74:2740-2751.
141. Pal S., Theodor I., Peterson E.M., de la Maza L. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 2001, 69:6240-6247.
142. Pantaleo G., Demarest J.F., Soudeyns H., Graziosi C., Denis F., Adelsberger J.W., Borrow P., Saag M.S., Shaw G.M., Sekaly R.P., Fauci A.S. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature 1994, 370:463-467.
143. Parr E.L., Kirby W.N. An immunoferritin labeling study of H-2 antigens on dissociated epithelial cells. J. Histochem. Cytochem. 1979, 27:1327-1336.
144. Parr E.L., McKenzie I.F.C. Demonstration of Ia antigens on mouse intestinal epithelial cells by immunoferritin labeling. Immunogenetics 1979, 8:499-508.
145. Parr M.B., Parr E.L. Mucosal immunity in the female and male reproductive tracts. Handbook of Mucosal Immunology 1994, 677-689. Academic Press, Austin, TX. P.L. Ogra (Ed.).
146. Parr M.B., Parr E.L. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 1999, 258:282-294.
147. Parr M.B., Parr E.L. Interferonγ up-regulates intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and recruits lymphocytes into the vagina of immune mice challenged with herpes simplex virus-2. Immunol. 2000, 99:540-545.
148. Parr M.B., Parr E.L. Vaginal immunity in the HSV-2 mouse model. Int. Rev. Immunol. 2003, 22:43-63.
149. Parren P.W., Moore J.P., Burton D.R., Sattentau O.J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999, 13(Supp A):S137-S162.
150. Pasquini S., Xiang Z., Wang Y., He Z., Deng H., Blaszczyk-Thurin M., Ertl H.C.J. Cytokines and costimulatory molecules as genetic adjuvants. Immunol. Cell Biol. 1997, 75:397-401.
151. Pavia C.S., Schachter J. Failure to detect cell-mediated cytotoxicity against Chlamydia trachomatis-infected cells. Infect. Immun. 1983, 39:1271-1274.
152. Perry L.L., Feilzer K., Caldwell H.D. Immunity to Chlamydia trachomatis is mediated by T Helper 1 cells through IFNγ dependent and -independent pathways. J. Immunol. 1997, 158:3344-3352.
153. Perry L.L., Su H., Feilzer K., Messer R., Hughes S., Whitmire W., Caldwell H.D. Differential sensitivity of distinct Chlamydia trachomatis isolates to IFNγ-mediated inhibition. J. Immunol. 1999, 162:3541-3548.
154. Ramsay A.J., Leong K.H., Ramshaw I.A. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol. Cell Biol. 1997, 75:382-388.
155. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: Exciting prospects for improved vaccination. Immunol. Today 2000, 21:163-165.
156. Rank R.G., Bowlin A.K., Kelly K.A. Characterization of lymphocyte response in the female genital tract during ascending chlamydial genital infection in the guinea pig model. Infect. Immun. 2000, 68:5293-5298.
157. Rank R.G., Ramsey K.H., Pack E.A., Williams D.M. Effect of gamma interferon on resolution of murine chlamydial genital infection. Infect. Immun. 1992, 60:4427-4429.
158. Rinaldo C., Huang X.-L., Fan Z., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M., Gupta P. High levels of anti-human immunodeficiency virus type-1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 1995, 69:5838-5842.
159. Roberts J.St.C., O'Neill T., Lacey C., Rowne D., Sterling J., Monteiro E., Clark L., Thompson S. Vaccine for genital warts. Vaccines for Human Papillomavirus Infection and Anogenital Disease 1999, 39-52. R. G. Landes Co., San Diego. R.W. Tindle (Ed.).
160. Robinson H.L. New Hope for an AIDS vaccine. Nat. Rev. Immunol. 2002, 2:239-250.
161. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., Rizvi T.A., Lu S., Hu S.-L., Mazzara G.P., Panicali D.L., Herndon J.G., Glickman R., Candido M.A., Lydy S.L., Wyand M.S., McClure H.M. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 1999, 5:526-534.
162. Rodriguez F., An L.L., Harkins S., Zhang J., Yokoyama M., Widera G., Fuller J.T., Kindcaid C., Campbell I.L., Whitton J.L. DNA immunization with minigenes: Low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J. Virol. 1998, 72:5174-5181.
163. Rodriguez F., Harkins S., Slifka M.K., Whitton J.L. Immunodominance in virus-induced CD8+ T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J. Virol. 2002, 76:4251-4259.
164. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., Montefiori D., Roberts A., Buonocore L., Rose J.K. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539-549.
165. Rosenberg E.S., Billingsley J.M., Caliendo A.M. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
166. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H., Blanchard T., Ariyoshi K., Oyugi J., Ngugi E., et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 1998, 102:1758-1768.
167. Royce R.A., Sena A., Cates W., et al. Sexual transmission of HIV. N. Engl. J. Med. 1997, 336:1072-1078.
168. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
169. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., Hill A.V.S. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4:397-402.
170. Schneider J., Gilbert S.C., Hannan C.M., Dégano P., Prieur E., Sheu E.G., Plebanski M., Hill A.V.S. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 1999, 170:29-38.
171. Schultz A. Encouraging vaccine results from primate models of HIV type 1 infection. AIDS Res. Hum. Retroviruses 1998, 14:S.
172. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., Hoffman S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 1998, 95:7648-7653.
173. Serre K., Machy P., Grivel J.-C., Jolly G., Brun N., Barbet J., Leserman L. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J. Immunol. 1998, 161:6059-6067.
174. Seth A., Ourmanov I., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., Wyatt L., Carroll M., Moss B., Venzon D., Letvin N.L., Hirsch V.M. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 2000, 74:2502-2509.
175. Shen X., Siliciano R.F. Preventing AIDS but not HIV-1 infection with a DNA vaccine. Science 2000, 290:463-465.
176. Shiver J.W., Fu T.-M., Chen L., Casimiro D.R., Davies M.-E., Evans R.K., Zhang Z.-Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-334.
177. Silverberg M.J., Ahdieh L., Muñoz A., Anastos K., Burk R.D., Cuuvin S., Duerr A., Greenblatt R.M., Klein R.S., Massad S., Minkoff H., Muderspach L., Palefsky J., Piessens E., Schuman P., Watts H., Shah K.V. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex. Transm. Dis. 2002, 29:427-435.
178. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA 2000, 97:811-816.
179. Skurnick J.H., Palumbo P., DeVico A., Shacklett B.L., Valentine F.T., Merges M., Kamin-Lewis R., Mestecky J., Denny T., Lewis G.K., Lloyd J., Praschunus R., Baker A., Nixon D.F., Stranford S., Gallo R., Vermund S.H., Louria D.B. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J. Infect. Dis. 2002, 185:428-438.
180. Smahel M., Sima P., Ludviková V., Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001, 281:231-238.
181. Smith S.M., Khoroshev M., Marx P.A., Orenstein J., Jeang K.T. Constitutively dead, conditionally live HIV-1 genomes: Ex vivo implications for a live virus vaccine. J. Biol. Chem. 2001, 276:32184-32190.
182. Stanley M.A. Immunobiology of papillomavirus infections. J. Reprod. Immunol. 2001, 52:45-59.
183. Starnbach M.N., Bevan M.J., Lampe M.F. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J. Immunol. 1994, 153:5183-5189.
184. Stittelaar K.J., Gruters R.A., Schutten M., van Baalen C.A., van Amerongen G., Cranage M., Liljeström P., Sutter G., Osterhaus A.D.M.E. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002, 20:2921-2927.
185. Stott J., Hu S.-L., Almond N. Candidate vaccines protect macaques against primate immunodeficiency viruses. AIDS Res. Hum. Retroviruses 1998, 14:S.
186. Su H., Messer R., Whitmire W., Fischer E., Portis J.C., Caldwell H.D. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable chlamydiae. J. Exp. Med. 1998, 188:809-818.
187. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.-Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408:605-609.
188. Sutter G., Haas J. Novel vaccine delivery systems: Solutions to HIV vaccine dilemmas?. AIDS 2001, 15:S139-S145.
189. Suzue K., Zhou X., Eisen H.N., Young R.A. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci. USA 1997, 94:13146-13151.
190. Tang Y., Villinger F., Staprans S.I., Amara R.R., Smith J.M., Herndon J.G., Robinson H.L. Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges. J. Virol. 2002, 76:10147-10154.
191. Thompson H.S.G., Davies M.L., Holding F.P., Fallon R.E., Mann A.E., O'Neill T., St.Clair Roberts J. Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999, 17:40-49.
192. Toes R.E.M., Hoeben R.C., van der Voort E.I.H., Ressing M.E., van der Eb A.J., Melief C.J.M., Offringa R. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci. USA 1997, 94:14660-14665.
193. Tseng C.-T.K., Rank R.G. Role of NK cells in early host response to chlamydial genital infection. Infect. Immun. 1998, 66:5867-5875.
194. van der Burg S.H., Kwappenberg K.M.C., O'Neill T., Brandt R.M.P., Melief C.J.M., Hickling J.K., Offringa R. Preclinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 19:3652-3660.
195. Velders M.P., McElhiney S., Cassetti M.C., Eiben G.L., Higgins T., Kovacs G.R., Elmishad A.G., Kast W.M., Smith L.R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 2001, 61:7861-7867.
196. Velders M.P., Weijzen S., Eiben G.L., Elmishad A.G., Kloetzel P.-M., Higgins T., Ciccarelli R.B., Evans M., Man S., Smith L., Kast W.M. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 2001, 166:5366-5373.
197. Veljkovic V., Metlas R., Köhler H., Urnovitz H.B., Prljic J., Veljkovic N., Johnson E., Müller S. AIDS epidemic at the beginning of the third millennium: Time for a new AIDS vaccine strategy. Vaccine 2001, 19:1855-1862.
198. Verhoef K., Marzio G., Hillen W., Bujard H., Berkhout B. Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J. Virol. 2001, 75:979-987.
199. Wagner R., Leschonsky B., Harrer E., Paulus C., Weber C., Walker B.D., Buchbinder S., Wolf H., Kalden J.R., Harrer T. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: Constraints on immune escape associated with targeting a sequence essential for viral replication. J. Immunol. 1999, 162:3727-3734.
200. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J.F., Peto J., Meijer C.J.L.M., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
201. Weiss R., Scheiblhofer S., Freund J., Ferreira F., Livey I., Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002, 20:3148-3154.
202. Wolkers M.C., Toebes M., Okabe M., Haanen J.B.A.G., Schumacher T.N.M. Optimizing the efficacy of epitope-directed DNA vaccination. J. Immunol. 2002, 168:4998-5004.
203. Wu T.-C., Guarnieri F.G., Staveley-O'Carroll K.F., Viscidi R.P., Levitsky H.I., Hedrick L., Cho K.R., August J.T., Pardoll D.M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA 1995, 92:11671-11675.
204. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 1999, 73:8356-8363.
205. Yasutomi Y., Reimann K.A., Lord C.I., Miller M.D., Letvin N.L. Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J. Virol. 1993, 67:1707-1711.
206. Zavala F., Rodrigues M., Rodrigues D., Rodriguez J.R., Nussenzweig R.S., Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8+ T cells. Virology 2001, 280:155-159.
207. Zhang D.-J., Yang X., Shen C., Lu H., Murdin A., Brunham R.C. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect. Immun. 2000, 68:3074-3078.
208. Zimet G.D., Mays R.M., Fortenberry J.D. Vaccines against sexually transmitted infections: Promise and problems of the magic bullets for prevention and control. Sex. Transm. Dis. 2000, 27:49-52.
209. Zur Megede J., Chen M.-C., Doe B., Schaefer M., Greer C.E., Selby M., Otten G.R., Barnett S.W. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 2000, 74:2628-2635.
210. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., van der Burg S.H., Melief C.J.M. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 2002, 169:350-358.